NCT05225051 (HO-HD) is a NA clinical trial of skin biopsy in Huntington Disease, sponsored by Central Hospital, Nancy, France.

Who is sponsoring NCT05225051?

NCT05225051 is sponsored by Central Hospital, Nancy, France.

What drugs are being tested in NCT05225051?

Interventions in NCT05225051: skin biopsy.

What condition does NCT05225051 study?

NCT05225051 studies Huntington Disease.

Is NCT05225051 still recruiting?

NCT05225051 is currently status unknown. Last updated 9 March 2022.

Last reviewed 2022-03-09 · How we verify

NCT05225051: HO-HD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

N- Homocysteinylated Huntingtin in Huntington's Disease

Status unknown NA Last updated 9 March 2022

What this trial tests

NA trial testing skin biopsy in Huntington Disease in 32 participants. Status unknown.

Timeline

1 April 2022

Primary endpoint
1 May 2023

1 May 2023

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	factorial
Masking	none
Primary purpose	basic science
Enrollment	32
Start date	1 April 2022
Primary completion	1 May 2023
Estimated completion	1 May 2023

Drugs / interventions tested

skin biopsy

Conditions studied

Huntington Disease — all drugs for Huntington Disease →

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Huntington Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Descriptive analysis of N- homocysteinylated Huntingtin in 3 groups of human fibroblasts: 1. presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin), 2. symptomatic HD individuals with motor UHDRS \> 5 (Mutated Huntingtin) 3. human control cell lines, unmutated Huntingtin

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of skin biopsy

Trials testing the same drug.

NCT07075107 — Transcriptomic Analysis of Fibroblasts and Blood in Patients With Rare Diseases · NA · not yet recruiting
NCT06444217 — Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HD · NA · recruiting
NCT06792487 — Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23) · recruiting
NCT06336473 — Evaluation of the Effects of Cross Linking on the Biomechanical Characteristics of Skin Samples From Patients With Class · NA · not yet recruiting
NCT06050330 — CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study · NA · completed

Other recruiting trials for Huntington Disease

Currently open trials in the same condition.

NCT07326709 — A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease · Phase 3 · recruiting
NCT07253038 — Evaluation of Three Tests to Assess Social Cognition in Huntington Disease · recruiting
NCT06774443 — Hinting Task for Huntington's Disease · recruiting
NCT06546488 — Cognitive Assessment Tools for Huntington's Disease. · recruiting
NCT07010705 — Digital Measures for Clinical Trial Endpoints in Huntington's Disease · recruiting

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05225051 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
Last refreshed: 9 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05225051.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing